Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Sep 3:S0140-6736(25)01335-2.
doi: 10.1016/S0140-6736(25)01335-2. Online ahead of print.

Enteric (typhoid and paratyphoid) fever

Affiliations
Review

Enteric (typhoid and paratyphoid) fever

Rebecca Kuehn et al. Lancet. .

Abstract

Enteric fever, caused by the human-restricted bacteria Salmonella enterica serovar Typhi (typhoid) and Salmonella enterica serovar Paratyphi A, B, and C (paratyphoid), affects persons residing in, or travelling from, areas lacking safe water, sanitation, and hygiene infrastructure. Transmission is by the faecal-oral route. A gradual fever onset over 3-7 days with malaise, headache, and myalgia is typical. Symptoms can be altered by previous antimicrobial use. Life-threatening complications can arise in the second week of untreated illness. Differentiation from other febrile illnesses is challenging. Blood or bone marrow culture remain reference standard diagnostic methods, despite the low sensitivity of blood culture. Azithromycin, ciprofloxacin (excepting cases originating in south Asia due to drug resistance), or ceftriaxone are recommended treatment options for both typhoid and paratyphoid; however, choice should be guided by local resistance patterns. Ciprofloxacin-resistant and ceftriaxone-resistant typhoid is common in Pakistan. Three vaccine types are available for prevention of typhoid disease, including the newer, more effective typhoid Vi-conjugate vaccines. Vaccination as well as water, sanitation, and hygiene measures are cornerstones of prevention.

PubMed Disclaimer

Conflict of interest statement

Declaration of interests AK, FNQ, and CMP are involved in the ACT-South Asia trial, which is funded by a Joint Global Health Trials Scheme (MR/TOO5033/1) award to the University of Oxford. RK is involved in the Research, Evidence and Development Initiative (READ-It; project number 300342-104), which is funded by the UK government. All other authors declare no competing interests.

LinkOut - more resources